Crossmark

CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia

Crossref DOI link: https://doi.org/10.1038/s41409-022-01845-w

Published Online: 2022-10-17

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yao, Zhenzhen

Gu, Bin https://orcid.org/0000-0001-9169-9635
Zhang, Yanming

Qi, Jiaqian

Chen, Jia

Xu, Yang

Chen, Feng https://orcid.org/0000-0002-7092-8483
Ma, Xiao

Miao, Miao

Xue, Shengli https://orcid.org/0000-0003-4609-616X
Qiu, Huiying

Tang, Xiaowen https://orcid.org/0000-0003-1766-7891
Han, Yue https://orcid.org/0000-0002-7560-7195
Chen, Suning

Sun, Aining

Yu, Lei

Wu, Depei https://orcid.org/0000-0002-6312-3863
Wang, Ying https://orcid.org/0000-0002-8015-3546
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81670164)

École Nationale d'Ingénieurs de Saint-Etienne (81730003)
License Information

Text and Data Mining valid from 2022-10-17

Version of Record valid from 2022-10-17
More Information

Article History

Received: 27 September 2022

Revised: 3 October 2022

Accepted: 4 October 2022

First Online: 17 October 2022

Competing interests

: LY is an employee of Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. The other authors declare no competing financial interests.

Document is current

Any future updates will be listed below